International Stem Cell Corporation Signs Agreement with BioTime, Inc., and Embryome Sciences, Inc., to Provide Unique Human Stem Cell Lines for Research Use, June 25, 2008

International Stem Cell Corporation’s Human Parthenogenetic Stem Cells to be used in the Development of Treatments for Liver Disease May 14, 2008

International Stem Cell Corporation Obtains Exclusive Rights in the US and Canada to Distribute Approved Human Skin Model for Toxicity Testing April 29, 2008

International Stem Cell Corporation to Present at LD Micro Conference April 29, 2008

International Stem Cell Corporation Announces Collaboration with The University of Cambridge to Study Parthenogenetic Stem Cells, April 9, 2008.

International Stem Cell Corporation Signs Letter of Intent with BioTime, Inc., and Embryome Sciences to Provide Unique Human Stem Cell Lines for Research Use, April 3, 2008.

International Stem Cell Corporation Announces Manufacturing and Supply Agreement with ATCC, March 31, 2008.

International Stem Cell Corporation’s Human Parthenogenetic Stem Cells to be used in Germany in the Development of Treatments for Neural Disease, February 28, 2008.

International Stem Cell Corporation to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference, January 29, 2008.

International Stem Cell Corporation Chairman adds CEO Role, January 22, 2008.

International Stem Cell Corporation Chairman Kenneth Aldrich to be Interviewed on WALLST.NET, January 18, 2008.

International Stem Cell Corporation to Provide Corneal Epithelial Cells Differentiated from its Parthenogenetic Stem Cells For Use in Photorefractive Keratectomy (PRK) FDA Clinical Trials, January 14, 2008.

Human Embryonic Stem Cell Lines Created That Avoid Immune Rejection in Large Segments of the Population, December 18, 2007.

HLA Homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts, December 18, 2007.

International Stem Cell Corporation CEO Issues Statement on De-Differentiation Research and Parthenogenesis, November 25, 2007.

International Stem Cell Names Noted Reproductive Endocrinologist to Scientific Advisory Board, September 17, 2007.

International Stem Cell Corporation Opens European Distribution Channel, Signs with CellSystems Biotechnologie Vertrieb, September 4, 2007.

International Stem Cell Corporation Contracts to Manufacture Adipose-Derived Stem Cells for Cytori Therapeutics, August 20, 2007.

International Stem Cell Corporation to Present at Roth Capital Partners New York Institutional Investor Conference September 5, 2007.

International Stem Cell Corporation Quoted in Bloomberg article on its Parthenogenetic Stem Cells, August 2, 2007.

International Stem Cell Corporation Subsidiary Lifeline Cell Technology Enters Into Agreement with University of California to Study Macular Degeneration and Retinitis Pigmentosa Mar. 19-07

Lifeline Cell Technology to Showcase Product Line at American Society for Cell Biology Conference Dec. 9-13, 2006 in San Diego

Lifeline Cell Technology® is an International Stem Cell company.